Cargando…

Serum neurofilament light chain in myasthenia gravis subgroups: An exploratory cohort and case–Control study

BACKGROUND: This study aimed to evaluate the association of neurofilament light chain (Nfl) with neuromuscular destruction and disease severity in the serum of patients with myasthenia gravis (MG). MATERIALS AND METHODS: Sera from 134 patients with MG with varying degrees of disease severity and aut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stascheit, Frauke, Aigner, Annette, Mergenthaler, Philipp, Hotter, Benjamin, Hoffmann, Sarah, Lehnerer, Sophie, Meisel, Christian, Meisel, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875128/ https://www.ncbi.nlm.nih.gov/pubmed/36712429 http://dx.doi.org/10.3389/fneur.2022.1056322

Ejemplares similares

Calprotectin as potential novel biomarker in myasthenia gravis
por: Stascheit, Frauke, et al.
Publicado: (2021)

Burden of disease in myasthenia gravis: taking the patient’s perspective
por: Lehnerer, Sophie, et al.
Publicado: (2021)

Correction to: Burden of disease in myasthenia gravis: taking the patient’s perspective
por: Lehnerer, Sophie, et al.
Publicado: (2022)

Myasthenia gravis - a retrospective analysis of e-mail inquiries made to a patient organisation and specialized center to uncover unmet needs from patients and caregivers
por: Stein, Maike, et al.
Publicado: (2022)

Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants—A Potential Novel Biomarker of Disease Activity
por: Stascheit, Frauke, et al.
Publicado: (2021)

Mental health in myasthenia gravis patients and its impact on caregiver burden
por: Marbin, Derin, et al.
Publicado: (2022)

Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis
por: Stascheit, Frauke, et al.
Publicado: (2022)

Eculizumab versus rituximab in generalised myasthenia gravis
por: Nelke, Christopher, et al.
Publicado: (2022)

Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients
por: Nelke, Christopher, et al.
Publicado: (2022)

Afterdischarges in Myasthenia Gravis
por: Yang, Li, et al.
Publicado: (2021)

Prediction of the generalization of myasthenia gravis with purely ocular symptoms at onset: a multivariable model development and validation
por: Li, Feng, et al.
Publicado: (2022)

IL-6 Plasma Levels Correlate With Cerebral Perfusion Deficits and Infarct Sizes in Stroke Patients Without Associated Infections
por: Hotter, Benjamin, et al.
Publicado: (2019)

Subgroup Classification of Myasthenia Gravis
por: Renjen, Pushpendra N.
Publicado: (2021)

Novel Treatments in Myasthenia Gravis
por: Menon, Deepak, et al.
Publicado: (2020)

Management of Juvenile Myasthenia Gravis
por: O'Connell, Karen, et al.
Publicado: (2020)

Controversies in Ocular Myasthenia Gravis
por: Evoli, Amelia, et al.
Publicado: (2020)

Immunoregulatory Cells in Myasthenia Gravis
por: Wu, Ying, et al.
Publicado: (2020)

Editorial: Phenotypes of myasthenia gravis
por: Li, Hai-Feng, et al.
Publicado: (2022)

Rituximab treatment in myasthenia gravis
por: Vesperinas-Castro, Ana, et al.
Publicado: (2023)

Role of complement in myasthenia gravis
por: San, Pyae Phyo, et al.
Publicado: (2023)

Fatigue in myasthenia gravis: risk factors and impact on quality of life
por: Hoffmann, Sarah, et al.
Publicado: (2016)

Evaluation of the Quantitative Myasthenia Gravis Score and Grip Strength in Chinese Patients With Myasthenia Gravis: An Observational Study
por: Li, Jinghao, et al.
Publicado: (2021)

Complement deposition at the neuromuscular junction in seronegative myasthenia gravis
por: Hoffmann, Sarah, et al.
Publicado: (2020)

Corticosteroid Treatment-Resistance in Myasthenia Gravis
por: Kaminski, Henry J., et al.
Publicado: (2022)

User Involvement in Myasthenia Gravis Research
por: Gilhus, Nils Erik, et al.
Publicado: (2022)

Myasthenia Gravis Presenting as Bulbar Palsy
por: Gosain, Dhruv, et al.
Publicado: (2023)

Social work support and unmet social needs in life after stroke: a cross-sectional exploratory study
por: Lehnerer, Sophie, et al.
Publicado: (2019)

Treatment of insomnia in myasthenia gravis—A prospective study on non-benzodiazepine hypnotics in the treatment of myasthenia gravis patients with insomnia
por: Yan, Jingwen, et al.
Publicado: (2023)

Myasthenia gravis: a clinical-immunological update
por: Binks, Sophie, et al.
Publicado: (2015)

Determinants of Quality of Life in Myasthenia Gravis Patients
por: Szczudlik, Piotr, et al.
Publicado: (2020)

A Review of Psychiatric Comorbidity in Myasthenia Gravis
por: Law, Christina, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-Induced Myasthenia Gravis
por: Huang, Yi-Te, et al.
Publicado: (2020)

Reappraisal of Oral Steroid Therapy for Myasthenia Gravis
por: Imai, Tomihiro, et al.
Publicado: (2020)

Myasthenia Gravis with Elderly Onset at Advanced Age
por: Hernandez Fustes, Otto Jesus, et al.
Publicado: (2020)

The Muscle Is Not a Passive Target in Myasthenia Gravis
por: Vilquin, Jean-Thomas, et al.
Publicado: (2019)

Editorial: News and Views in the Management of Myasthenia Gravis
por: Evoli, Amelia, et al.
Publicado: (2021)

Application of lymphoplasmapheresis in the treatment of severe myasthenia gravis
por: Duan, Weiwei, et al.
Publicado: (2022)

Galcanezumab-Induced Myasthenia Gravis-Like Symptoms
por: Mubaraki, Adnan A
Publicado: (2023)

A Case of Pembrolizumab-Induced Myasthenia Gravis
por: Kosick, Thomas I, et al.
Publicado: (2023)

Quantitative motor assessment of muscular weakness in myasthenia gravis: a pilot study
por: Hoffmann, Sarah, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nvnll5n5d9sbi0ep4nmf4la3p1